GOOGL   1,518.66 (+1.00%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
GOOGL   1,518.66 (+1.00%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
GOOGL   1,518.66 (+1.00%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
GOOGL   1,518.66 (+1.00%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
Log in

NYSE:BSXBoston Scientific Stock Price, Forecast & News

$34.50
-0.05 (-0.14 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.77
Now: $34.50
$34.75
50-Day Range
$33.28
MA: $36.22
$39.11
52-Week Range
$24.10
Now: $34.50
$46.62
Volume12.18 million shs
Average Volume11.90 million shs
Market Capitalization$48.28 billion
P/E Ratio11.35
Dividend YieldN/A
Beta0.92
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Read More
Boston Scientific logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.27 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP10113710
Phone508-683-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.74 billion
Cash Flow$2.39 per share
Book Value$9.96 per share

Profitability

Net Income$4.70 billion

Miscellaneous

Employees36,000
Outstanding Shares1,399,350,000
Market Cap$48.28 billion
Next Earnings Date7/29/2020 (Confirmed)
OptionableOptionable

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Boston Scientific (NYSE:BSX) Frequently Asked Questions

How has Boston Scientific's stock been impacted by COVID-19 (Coronavirus)?

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BSX stock has increased by 1.8% and is now trading at $34.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Boston Scientific?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Boston Scientific.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Boston Scientific.

How can I listen to Boston Scientific's earnings call?

Boston Scientific will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) issued its quarterly earnings data on Wednesday, April, 29th. The medical equipment provider reported $0.28 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.33 by $0.05. The medical equipment provider had revenue of $2.54 billion for the quarter, compared to the consensus estimate of $2.54 billion. Boston Scientific had a net margin of 39.75% and a return on equity of 18.24%. The firm's revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.35 EPS. View Boston Scientific's earnings history.

What price target have analysts set for BSX?

24 equities research analysts have issued 1 year price objectives for Boston Scientific's stock. Their forecasts range from $25.00 to $58.00. On average, they expect Boston Scientific's stock price to reach $44.65 in the next year. This suggests a possible upside of 29.5% from the stock's current price. View analysts' price targets for Boston Scientific.

Has Boston Scientific been receiving favorable news coverage?

News coverage about BSX stock has been trending negative on Thursday, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Boston Scientific earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Boston Scientific.

Who are some of Boston Scientific's key competitors?

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Bank of America (BAC), CVS Health (CVS), salesforce.com (CRM), Johnson & Johnson (JNJ), AT&T (T), Home Depot (HD) and Visa (V).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the following people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 55, Pay $3.57M)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 54, Pay $1.28M)
  • Mr. Edward F. Mackey, Exec. VP of Operations (Age 57, Pay $1.13M)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 56, Pay $1.24M)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 47, Pay $1.07M)

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.05%), Robecosam AG (0.05%), DNB Asset Management AS (0.03%), State of Alaska Department of Revenue (0.02%), First American Trust FSB (0.01%) and Private Trust Co. NA (0.00%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori. View institutional ownership trends for Boston Scientific.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including Robecosam AG, State of Alaska Department of Revenue, and Paragon Advisors LLC. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, and Wendy Carruthers. View insider buying and selling activity for Boston Scientific.

Which major investors are buying Boston Scientific stock?

BSX stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., First American Trust FSB, Fulton Bank N. A., Platte River Wealth Advisors LLC, Mount Yale Investment Advisors LLC, Canandaigua National Corp, DNB Asset Management AS, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu, and Williamson Scott. View insider buying and selling activity for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $34.48.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $48.25 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe.

What is Boston Scientific's official website?

The official website for Boston Scientific is www.bostonscientific.com.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.